The web Directory of Information Materials for People Affected by Cancer is regularly updated and currently has details of over 1,900 booklets, leaflets, books and audiovisual materials for people affected by cancer. Most have been published in the last five years but we have included some older ones that are still useful.
Please enter a word or phrase into the search box to find relevant materials. If you want to search for a phrase, please use quotes, eg “Macmillan Cancer Support”, “Breast cancer”. If you have any questions about the web directory please contact Sue Hawkins email@example.com
Newer antibodies against CD20 are beginning to offer alternatives to rituximab for some people with lymphoma. This factsheet covers: antibodies targeting CD20; ofatumumab (Arzerra®); obinutuzumab (Gazyvaro®). It considers who can have these antibodies, how they are given, possible side effects.
This factsheet is about the monoclonal antibody rituximab in the treatment of lymphoma. It tells you how rituximab works, who might be given it and what to expect during treatment.
Brentuximab vedotin is a targeted drug used in the treatment of certain types of lymphoma. This factsheets explains what it is, who can have it, how it is given, the benefits and possible side effects.
Macmillan Cancer Support
Nivolumab (OPDIVO®) is a targeted therapy drug used to treat melanoma, non-small cell lung cancer or kidney (renal cell) cancer.
Macmillan Cancer Support
Ipilimumab is a targeted therapy drug used to treat advanced melanoma. This describes how it works, how it is given, and some of the possible side-effects.
Daratumumab, also known as Darzalex®, is a monoclonal antibody drug used in the treatment of myeloma. This booklet describes what it is, how it works, how it is given, and the possible side-effects.
Isatuximab is a new drug that is being investigated for the treatment of myeloma. This factsheet describes briefly what it is, how it works, how it is given, the possible benefits over existing drugs, the possible side-effects, and its availability in the UK.
Elotuzumab is a new drug that is being investigated for the treatment of myeloma. This factsheet describes briefly what it is, how it works, how it is given, the possible benefits over existing drugs, the possible side-effects, its availability in the UK, and the future.
This treatment guide has information about thalidomide, a drug used in the treatment of myeloma. It explains what it is, how it works, and how it is given, and describes the possible side-effects.